储存血小板释放PDL1对T细胞功能的影响

陈绍恒 ,  潘楠楠 ,  李品品 ,  王莉莉 ,  郑俊 ,  徐凤程 ,  邓慧敏 ,  张军

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1231 -1236.

PDF (3432KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1231 -1236. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.09.010
论著

储存血小板释放PDL1对T细胞功能的影响

作者信息 +

Effects of PD-L1 released from stored platelets on T cell function

Author information +
文章历史 +
PDF (3513K)

摘要

目的 研究在储存过程中血小板释放来源的程序性死亡配体-1(programmed death-ligand 1,PDL1)对 T 细胞增殖、凋亡及细胞因子表达的影响。方法 单采血小板在 22℃振荡储存,分别于 d1、d3、d5、d7 收集血小板上清液,然后分别与磁珠分选的人 CD4+和 CD8+混合 T 细胞共培养,利用 CCK8 试剂盒检测 T 细胞增殖、流式检测 T 细胞凋亡及 INFγ 和 GZMB 表达的改变。 此外,利用 western-blot 检测程序性死亡受体-1(programmed cell death protein-1,PD1)受体下游相关信号分子表达的改变。结果 随着血小板储存时间的延长,保存液对 T 细胞增殖的抑制作用逐渐增强,并抑制 INFγ 和 GZMB 表达; 而 T 细胞凋亡水平逐渐增加。 当加入 PD-1 抗体或 PDL1 抗体后,可一定程度上阻断血小板储存介质对上述 T 细胞增殖、凋亡和 INFγ 和 GZMB 表达的影响。 通过 western-blot 结果分析显示,血小板保存液共培养组的 T 细胞 p-SHP1 和 p-SHP 2 表达水平明显上调,并伴随 pAKT 下调;当加入 PD-1 抗体或 PDL1 抗体之后,可以部分逆转上述蛋白表达水平。结论 随着储存时间的延长,保存液中的血小板来源的 PDL1 会促进 T 细胞凋亡,抑制其增殖及相关细胞因子的表达。 因此,血小板来源的 PDL1 作为一种免疫调节介质可能参与输血相关免疫调节(transfusion-related immunomodulation,TRIM)。

Abstract

Objective To investigate the effects of platelet-derived PD-L1 released during storage on T cell proliferation, apoptosis, and cytokine expression. Methods Apheresis platelets were stored with agitation at 22℃. Platelet supernatant was collected on days 1, 3, 5, and 7 of storage, and then co-cultured with human CD4+ and CD8+ mixed T cells isolated by magnetic bead sorting. CCK8 assay was used to detect T cell proliferation; flow cytometry was applied to determine T cell apoptosis as well as the expression levels of IFN-γ and GZMB. Additionally, Western blot was employed to examine alterations in downstream signaling molecules of the PD-1 receptor. Results With the prolongation of platelet storage time, the inhibitory effect of platelet storage medium on T cell proliferation was gradually enhanced, accompanied by suppressed expression of IFN-γ and GZMB, whereas the apoptosis level of T cells increased progressively. Treatment with PD-1 antibody or PD-L1 antibody partially blocked the regulatory effects of platelet storage medium on T cell proliferation, apoptosis, and the expression of IFN-γ and GZMB. Western blot results showed that the phosphorylation levels of p-SHP1 and p-SHP2 were significantly upregulated, whereas p-AKT expression was downregulated in T cells co-cultured with platelet storage medium. Intervention with PD-1 or PD-L1 antibody could partially reverse the above changes in protein expression. Conclusion During platelet storage, platelet-derived PD-L1 in the storage medium promotes T cell apoptosis and inhibits T cell proliferation as well as the expression of related cytokines in a time-dependent manner. Therefore, platelet-derived PD-L1, as an important immune regulatory mediator, may be involved in transfusion-related immunomodulation (TRIM).

关键词

血小板储存 / PDL1 / T 细胞功能 / 输血相关免疫调节

Key words

platelet storage / PD-L1 / T cell function / transfusion-related immunomodulation

引用本文

引用格式 ▾
陈绍恒,潘楠楠,李品品,王莉莉,郑俊,徐凤程,邓慧敏,张军. 储存血小板释放PDL1对T细胞功能的影响[J]. 中国输血杂志, 2026, 39(9): 1231-1236 DOI:10.13303/j.cjbt.issn.1004-549x.2026.09.010

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

HEGDE S, AKBAR H, WELLENDORF A M, et al. Inhibition of RHOA activity preserves the survival and hemostasis function of long-term cold-stored platelets[J].Blood, 2024, 144(16):1732-1746.

[2]

WANG S, LIU Q, CHENG L, et al. Targeting biophysical cues to address platelet storage lesions[J].Acta Biomater, 2022, 151:118-133.

[3]

LIU C, SU Y, GUO W, et al. The platelet storage lesion, what are we working for[J].J Clin Lab Anal, 2024, 38(1-2):e24994.

[4]

WINSKEL-WOOD B, MARKS D C, JOHNSON L. Storage temperature affects platelet activation and degranulation in response to stimuli[J].Int J Mol Sci, 2025, 26:2944.

[5]

JACKMAN R P, THOMAS K A. Immune response to platelet transfusions[J].Curr Opin Hematol, 2025, 32:357-363.

[6]

LIN X, KANG K, CHEN P, et al. Regulatory mechanisms of PD-1/ PD-L1 in cancers[J].Mol Cancer, 2024, 23:108.

[7]

GAO M, SHI J, XIAO X, et al. PD-1 regulation in immune homeostasis and immunotherapy[J].Cancer Lett, 2024, 588:216726.

[8]

CHEN S, HAN J, DENG H, et al. Platelet PD-L1 inhibits storage-induced apoptosis by sustaining activation of the AKT signalling pathway[J].Thromb Res, 2024, 240:109056.

[9]

KUMAR V, STEWART I J. Platelet's plea to Immunologists:Please do not forget me[J].Int Immunopharmacol, 2024, 143:113599.

[10]

GOLEBIEWSKA E M, POOLE A W. Platelet secretion: From haemostasis to wound healing and beyond[J].Blood Rev, 2015, 29:153-162.

[11]

CAI Z, FENG J, DONG N, et al. Platelet-derived extracellular vesicles play an important role in platelet transfusion therapy[J].Platelets, 2023, 34:2242708.

[12]

KUBAEV A, FAEZ S F, PIROUZBAKHT M, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis[J].J Liposome Res, 2025, 35:334-344.

[13]

SARIS A, PEYRON I, VAN DER MEER P F, et al. Storage-induced platelet apoptosis is a potential risk factor for alloimmunization upon platelet transfusion[J].Front Immunol, 2018, 9:1251.

[14]

TROCHANOWSKA-PAUK N, WALSKI T, BOHARA R, et al. Platelet storage-problems, improvements, and new Perspectives[J].Int J Mol Sci, 2024, 25(14):7779.

[15]

RACHIDI S, METELLI A, RIESENBERG B, et al. Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis[J]. Sci Immunol, 2017, 2:eaan2797.

[16]

ZHU L, HUANG Z, STALESEN R, et al. Platelets provoke distinct dynamics of immune responses by differentially regulating CD4+ T-cell proliferation[J].J Thromb Haemost, 2014, 12(7):1156-1165.

[17]

SHARMA P, GOSWAMI S, RAYCHAUDHURI D, et al. Immune checkpoint therapy-current perspectives and future directions[J].Cell, 2023, 186(8):1652-1669.

[18]

KIM W, CHU T H, NIENHÜSER H, et al. PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice[J].Gastroenterology, 2020, 159(3):971-984. e6.

[19]

PATSOUKIS N, WANG Q, STRAUSS L, et al. Revisiting the PD-1 pathway[J].Sci Adv, 2020, 6 (36):eabd2712.

[20]

GONG B, KIYOTANI K, SAKATA S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer[J].J Exp Med, 2019, 216(5):982-1000.

[21]

ZHOU J, MAHONEY K M, GIOBBIE-HURDER A, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade[J].Cancer Immunol Res, 2017, 5(6):480-492.

[22]

MAHONEY K M, SHUKLA S A, PATSOUKIS N, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression[J].Cancer Immunol Immunother, 2019, 68 (3):421-432.

[23]

MANNE B K, XIANG S C, RONDINA M T. Platelet secretion in inflammatory and infectious diseases[J]. Platelets, 2017, 28(2):155-164.

[24]

LIU S, GUO B, SONG L, et al. Platelet-derived transforming growth factor-beta1:A new hope for cerebral malaria treatment[J].ACS Infect Dis, 2025, 11 (11):3021-3029.

[25]

KUCHROO J R, GOLDMAN N, SHARPE A H. PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease[J].Nat Rev Rheumatol, 2026, 22(2):89-104.

[26]

TAUBER P A, RULAND J. T cell lymphomas:cancers of aberrant immune synapse signalling[J].Nat Rev Immunol, 2026,26(5):315-329.

基金资助

中国输血协会威高科研基金资助项目(CSBT-WG-2024-08)

上海市第一人民医院特色研究项目资助(CCTR-2025C47)

上海市青浦区科技发展基金社会发展(医疗卫生)项目(QKY2025-80)

AI Summary AI Mindmap
PDF (3432KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉